FOXO4-DRI: the peptide senolytic targeting the FOXO4-p53 interaction

FOXO4-DRI is a synthetic peptide built to selectively kill senescent cells. it carries a short stretch of FOXO4 sequence from the FOXO4-p53 interaction interface, made of D-amino acids in reversed order so that it resists proteases, fused to a HIV-TAT segment for cell entry. the evidence base is essentially one foundational mouse paper plus a small set of follow-ups; no human trials have been completed.

what is FOXO4-DRI?

FOXO4-DRI stands for FOXO4 D-Retro-Inverso. the active region is derived from human FOXO4 at the protein-protein interface that contacts p53. it is built using D-amino acids in a reversed sequence, then fused to a HIV-TAT cell-penetrating segment. the result is a roughly 40-residue peptide engineered to disrupt a single intracellular protein interaction.

the peptide was reported by the Baar lab at Erasmus University Medical Center in Rotterdam, led by Marjolein P. Baar with Peter L.J. de Keizer as senior author, in the 2017 Cell paper that introduced the molecule to the broader scientific community [1]. the design hypothesis was specific: senescent cells overexpress FOXO4 and use a direct FOXO4-p53 interaction to sequester p53 away from its mitochondrial pro-apoptotic role. disrupting that single protein-protein interaction should selectively release p53 and trigger apoptosis only in senescent cells, leaving healthy cells alone.

the chemistry is deliberate. D-retro-inverso construction reverses the parent peptide sequence and switches every residue from L to D stereochemistry. mammalian proteases are stereoselective and cannot cleave D-amide bonds efficiently, so the peptide gains substantial plasma stability over a parent L-peptide [2]. the HIV-TAT segment provides cell penetration, which is essential because the target interaction sits inside the nucleus. the Erasmus team later spun out Cleara Biotech to advance second-generation FOXO4-targeting senolytic candidates toward IND-enabling work, although no Cleara molecule has entered Phase 1 as of mid-2026.

how does it work?

senescent cells use a direct FOXO4-p53 interaction to keep active p53 trapped in nuclear bodies and away from its mitochondrial pro-apoptotic role. FOXO4-DRI enters the cell via TAT-mediated uptake, binds the p53 transactivation domain (p53TAD2), and displaces endogenous FOXO4. p53 then redistributes to the cytoplasm and mitochondria, BAX is activated, and caspase-3 cleavage triggers apoptosis. selectivity comes from the fact that healthy cells do not rely on the FOXO4-p53 complex for survival.

the underlying biology is striking. senescent cells accumulate DNA damage, upregulate the cell-cycle inhibitors p21 and p16INK4A, develop a senescence-associated secretory phenotype (SASP), and become paradoxically resistant to apoptosis despite chronic stress. p53 in these cells is present and active but its pro-apoptotic mitochondrial program is blunted. one of the brakes is a direct FOXO4-p53 interaction that traps active p53 in PML-associated DNA damage foci, preventing mitochondrial translocation [3].

a 2025 NMR study directly mapped FOXO4-DRI binding to the disordered p53TAD2 region, supporting the originally proposed mechanism with structural data. the same work showed that FOXO4-DRI behaves as a disordered ligand that forms a transiently folded complex with disordered p53TAD2, which has implications for how to optimize binding affinity in next-generation analogs [4]. downstream signaling in follow-up papers fits the proposed model: senescent endothelial cells exposed to FOXO4-DRI activate a p53-to-BAX-to-cleaved-caspase-3 axis with BCL-2 suppression, and senescent Leydig cells undergo p53 nuclear exclusion and apoptosis.

what does the evidence show?

the entire FOXO4-DRI direct-evidence base is preclinical. the Baar 2017 paper is the foundational study, with aged-mouse rescue findings (fur, mobility, renal markers) and a chemotherapy-induced-senescence experiment. follow-on papers extend the result to in vitro human chondrocytes, lung fibrosis in mice, vascular and reproductive aging in mice. no controlled human trials of FOXO4-DRI have been registered or completed.

the headline Baar 2017 results: naturally aged C57BL/6 mice given intraperitoneal FOXO4-DRI at 5 mg/kg in a pulsed schedule of three doses over five days, repeated weekly for up to three weeks, recovered fur density and coat appearance within weeks. treated mice also recovered running-wheel performance and grip strength, consistent with a global reduction in senescent-cell burden. renal function markers improved in both aged wild-type and accelerated-aging XpdTTD/TTD mice without overt toxicity at the doses tested. in a separate experiment, doxorubicin-pretreated mice given FOXO4-DRI showed accelerated recovery of fur, fitness, and renal function. this is the most therapeutically translatable claim in the original paper, because the target population (cancer survivors with chemotherapy-induced senescent-cell burden) is well-defined and the treatment window is bounded.

the follow-up literature is small but growing. a 2021 study confirmed selective senolytic activity in late-passage human chondrocytes and improved chondrogenic quality. a 2023 mouse study in bleomycin-induced pulmonary fibrosis reported reduced senescent-cell burden, lowered SASP factor expression, and attenuated collagen deposition with effects comparable in magnitude to pirfenidone in the same model [5]. more recent 2025-2026 papers from Chinese research groups report reduced markers of endothelial cell senescence and improved markers of vascular function in mouse models, and a separate line of work reports selective reduction of senescent Leydig cells in aged mice with associated improvements in testosterone secretion. replication outside the single-lab groups producing each finding is still limited.

the largest honest framing point is that the literature is dominated by one paper plus a small set of follow-ups, many in narrower models. no Phase 1 trial of FOXO4-DRI has been registered as of mid-2026, no human pharmacokinetic data exist, and even mouse dose-response curves have not been published. the senolytic class itself has produced sobering precedents: UBX0101 advanced to Phase 2 in knee osteoarthritis and failed the primary efficacy endpoint, leading Unity Biotechnology to discontinue the program in 2020.

FDA and regulatory status

FOXO4-DRI is not FDA-approved for any indication. it is not on the FDA 503A bulk drug substance compounding pathway, no Phase 1 trial has been registered, and a ClinicalTrials.gov search for "FOXO4" returns no registered interventional efficacy trials. WADA does not list the molecule by name; it would fall under section S0 (non-approved substances) as a research peptide without therapeutic approval.

the practical regulatory implication is that the only legitimate sources of FOXO4-DRI are research laboratories synthesizing it for internal use and a small number of clinical-stage developers preparing IND-enabling work. it is widely marketed online by gray-market vendors as a "research peptide," and independent third-party HPLC verification reportedly identifies substantial variance across vendor lots [6]. the "research use only" labeling has no regulatory force regarding quality, and buyers typically cannot reliably distinguish authentic FOXO4-DRI from peptides with partial sequence, wrong stereochemistry, or low purity.

manufacturing is also a real practical barrier. solid-phase peptide synthesis with D-amino acid building blocks is significantly more expensive than standard L-peptide synthesis, and a roughly 40-residue DRI peptide accumulates impurities at scale. Cleara Biotech's second-generation candidates (e.g., CL04177, CL04183) are part of an effort to improve developability for clinical translation, but as of mid-2026 none has reached the clinic [7].

safety profile and side effects

in the Baar 2017 paper, treated mice showed no overt weight loss, no organ toxicity, and no perturbation of standard blood panels across the tested dose levels and durations. selectivity for senescent cells was reinforced by the observation that healthy cells did not undergo apoptosis upon FOXO4-DRI exposure in vitro. mouse tolerability does not equal human safety, and no maximum tolerated dose or dose-limiting toxicity study has been published in any species.

the theoretical safety concerns specific to FOXO4-DRI rest on three categories. first, acute apoptotic clearance of senescent cells in vulnerable tissues could in principle produce transient inflammatory bursts, by analogy with navitoclax and other senolytic classes. second, immunogenicity from the HIV-TAT fusion is theoretically possible with chronic exposure, although TAT has been used in many peptide drug-delivery contexts without major issues. third, and most subtly, transient senescence is genuinely beneficial during wound healing and embryonic development. over-aggressive senolysis could in principle impair these processes, although the clinical relevance of this risk in adult populations is unclear.

in practical terms, anecdotal community reports from peptide-user sources include local injection-site reactions (typical for any subcutaneous peptide) and occasional flu-like symptoms in the post-dose window. none of these are documented in controlled studies, the underreporting bias is severe for non-approved compounds, and batch-specific quality issues can mimic intrinsic drug toxicity.

where it fits in peptide therapy

FOXO4-DRI is the only peptide-based senolytic with significant published evidence. small-molecule senolytics include dasatinib plus quercetin, fisetin, navitoclax, and UBX0101. each targets a different senescent-cell anti-apoptotic pathway, and dasatinib plus quercetin and fisetin have early human pilot data that FOXO4-DRI does not.

the closest small-molecule senolytics with published human pilot data are dasatinib plus quercetin (D+Q), a kinase-inhibitor-plus-flavonoid cocktail that has been tested in idiopathic pulmonary fibrosis and diabetic kidney disease, and fisetin, a flavonoid in early human pilots in Alzheimer's, frailty, and post-transplant settings [8]. navitoclax is a potent BCL-2/BCL-XL inhibitor whose development as a senolytic is limited by on-target platelet toxicity. UBX0101 was a p53/MDM2 inhibitor that reached Phase 2 in knee osteoarthritis and failed efficacy versus placebo, which is the most important translational-failure data point in the senolytic class.

FOXO4-DRI is mechanistically orthogonal to all of these because its target is the FOXO4-p53 interaction, a protein-protein interface not addressed by kinase or BCL-2 family inhibitors. it sits outside the rest of our peptide map: it does not share biology with the tissue-repair peptides like BPC-157 or TB-500, with the GH-axis peptides like tesamorelin and sermorelin, or with the metabolic peptides like semaglutide. for foundational biology on how senescence and the hallmarks of aging interact with the rest of peptide pharmacology, see our free peptides and your body module.